Table 2.
Receiver operating characteristic (ROC) curves analysis for distinguishing cancer patients from controls.
| Parameter | stage | Sensitivity | Specificity | ROC Curve Area | P Value | ACC | Sensitivity at 90% |
|---|---|---|---|---|---|---|---|
| (95% Cl) | (95% Cl) | (95% Cl) | Specificity | ||||
| IgG/IgM ratio | all | 60.3% (47.2% - 72.4%) | 60.8% (53.6% - 67.7%) | 0.636 (55.9% - 71.4%) | 0.0012 | 0.603 | 26.8% |
| IgG/IgM ratio | 0-3a | 60.3% (47.2% - 72.4%) | 64.7% (56.5% - 72.3%) | 0.651 (57.2% - 73.1%) | 0.0005 | 0.620 | 28.7% |
| IgG/IgA ratio | all | 60.7% (46.8% - 73.5%) | 58.8% (51.5% - 65.8%) | 0.636 (54.8% - 72.3%) | 0.0020 | 0.592 | 17.0% |
| IgG/IgA ratio | 0-1 | 66.1% (52.2% - 72.2%) | 65.6% (52.7% - 77.1%) | 0.690 (59.4% - 78.7%) | 0.0003 | 0.658 | 21.9% |
| SNA binding | all | 63.6% (49.5% - 76.2%) | 60.5% (53.3% - 67.4%) | 0.658 (57.6% - 74.0%) | 0.0003 | 0.612 | 23.1% |
| SNA binding | 1-2a, b | 63.6% (49.6% - 76.2%) | 61.3% (51.4% - 70.6%) | 0.659 (57.1% - 74.7%) | 0.0009 | 0.621 | 24.5% |
| SNA/IgG index | all | 66.7% (49.0% - 81.4%) | 65.3% (58.1% - 72.0%) | 0.706 (61.0% - 80.3%) | < 0.0001 | 0.651 | 32.1% |
| SNA/IgG index | 0+1 | 69.4% (51.8% - 83.7%) | 70.3% (57.6% - 81.1%) | 0.754 (65.2% - 85.5%) | < 0.0001 | 0.700 | 39.1% |
| SNA/IgA index | all | 58.3% (40.8% - 74.5%) | 80.3% (74.0% - 85.7%) | 0.793 (71.0% - 87.7%) | < 0.0001 | 0.769 | 49.2% |
| SNA/IgA index | 0+1 | 58.3% (40.8% - 74.5%) | 87.5% (76.9% - 94.5%) | 0.833 (74.7% - 91.8%) | < 0.0001 | 0.770 | 62.5% |
| IgA avidity index | 1-3a | 75.0% (56.6% - 88.5%) | 82.2% (74.4% - 88.3%) | 79.7% (70.1% - 89.3%) | < 0.0001 | 0.808 | 33.3% |
The diagnostic sensitivity, specificity, and accuracy for representative parameters studied at different stages of cancer. The area under the curve (AUC) with 95% confidence interval (CI), the accuracy of diagnostics (ACC), and P values are presented. AUC: the area under the receiver operator curve (ROC).